Holen Sie sich die Stockscreener-App
0.65
0.81%
0.0052
Handel nachbörslich:
.64
-0.01
-1.54%
Schlusskurs vom Vortag:
$0.6448
Offen:
$0.66
24-Stunden-Volumen:
52,564
Relative Volume:
0.38
Marktkapitalisierung:
$7.19M
Einnahmen:
$1.52M
Nettoeinkommen (Verlust:
$-70.60M
KGV:
-0.061
EPS:
-10.65
Netto-Cashflow:
$-57.34M
1W Leistung:
+6.96%
1M Leistung:
-4.41%
6M Leistung:
-43.72%
1J Leistung:
-77.82%
1-Tages-Spanne:
$0.621
$0.66
1-Wochen-Bereich:
$0.581
$0.667
52-Wochen-Spanne:
$0.5719
$3.50
Pavmed Inc Stock (PAVM) Company Profile
Firmenname
Pavmed Inc
Sektor
Branche
Telefon
(212) 949-4319
Adresse
360 MADISON AVENUE, NEW YORK, NY
Vergleichen Sie PAVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
0.65 | 7.19M | 1.52M | -70.60M | -57.34M | -10.65 |
|
ABT
Abbott Laboratories
|
113.48 | 196.83B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
383.42 | 146.17B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
98.66 | 145.41B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.08 | 112.94B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.78 | 41.16B | 6.60B | 4.16B | 490.10M | 6.93 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Eingeleitet | Maxim Group | Buy |
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
PAVmed shareholders approve stock issuance and charter amendment - Investing.com India
Lucid Diagnostics Achieves Record-Breaking Quarter with 84% Surge in EsoGuard DNA Test Volume - StockTitan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit - Kilgore News Herald
Lucid Inks New Partnership With VITALExam: Stock to Gain? - MSN
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophag - GuruFocus.com
Lucid Gains Extension of Compliance by NASDAQ - Baystreet.ca
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - Marketscreener.com
Lucid Diagnostics Gets Nasdaq Extension to Meet $1 Listing Requirement Through June 2025 - StockTitan
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Eastern Progress Online
Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters - GuruFocus.com
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test - The Eastern Progress Online
PAVmed stock plunges to 52-week low, touches $0.6 By Investing.com - Investing.com Canada
PAVmed stock plunges to 52-week low, touches $0.6 - Investing.com
Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World
PAVmed (NASDAQ:PAVM) versus Embecta (NASDAQ:EMBC) Financial Review - Defense World
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuar - GuruFocus.com
Lucid Diagnostics' EsoGuard Shows Breakthrough 85% Compliance Rate in Major Clinical Study - StockTitan
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication (PR Newswire) - Aktiellt
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication - PR Newswire
PAVmed (NASDAQ:PAVM) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World
Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health - The Eastern Progress Online
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones - Lelezard
Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones – Company AnnouncementFT.com - Financial Times
Lucid Diagnostics Secures $21.95M Convertible Note Financing, Extends Cash Runway - StockTitan
Symbol Lookup - GuruFocus.com
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Vi - GuruFocus.com
PAVmed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Diagnostics Provides Business Update and Third Quarter 202 - GuruFocus.com
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test - PR Newswire
PAVmed Q3 2024 Earnings Preview - MSN
Lucid Diagnostics Seeks Medicare Coverage for EsoGuard Test with New Clinical Data - StockTitan
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, D - GuruFocus.com
PAVmed Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
LUCDLucid Diagnostics Inc. Latest Stock News & Market Updates - StockTitan
Earnings call: PAVmed reports strategic shifts and Q3 financials - Investing.com
PAVmed Inc. (NASDAQ:PAVM) Q3 2024 Earnings Call Transcript - Insider Monkey
PAVmed Inc. (PAVM) Quarterly 10-Q Report - Quartzy
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring - Yahoo Finance
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Reven - GuruFocus.com
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring By GuruFocus - Investing.com Canada
First Manhattan Co. LLC's Strategic Acquisition of PAVmed Inc Sh - GuruFocus.com
PAVmed Inc Reports Q3 2024 Earnings: Revenue at $996,000, Non-GA - GuruFocus.com
PAVmed Reports Record Revenue and Strategic Restructuring - TipRanks
PAVmed Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 - Kilgore News Herald
PAVMPAVmed Inc. Latest Stock News & Market Updates - StockTitan
Lucid Diagnostics' EsoGuard Revenue Surges 50% YoY, Sets Record Testing Volume in Q3 | PAVM Stock News - StockTitan
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results - PR Newswire
PAVmed's Earnings: A Preview - Benzinga
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication – Company AnnouncementFT.com - Financial Times
Finanzdaten der Pavmed Inc-Aktie (PAVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):